- Ethyreal lands $101M to treat both Graves' and thyroid eye diseaseA biotech backed by Atlas Venture and Medicxi uncloaked on Wednesday morning to tackle the related autoimmune conditions Graves' disease and thyroid eye disease, and the startup plans to enter the…Endpoints · 1mo ago↗ source
- Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studySanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of t…Endpoints · 1mo ago↗ source
- Parabilis' $670M IPO sets new biotech record, will fund cancer drugDespite all the noise around massive upcoming IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever s…